SLDB250117P2500
- 0.05
- 0.000.00%
Solid Biosciences Newsroom
William Blair Maintains Solid Biosciences(SLDB.US) With Buy Rating
JMP Securities Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $15
Promising Developments and Strategic Advancements Support Buy Rating for Solid Biosciences
Solid Biosciences Analyst Ratings
H.C. Wainwright Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $16
Solid Biosciences' Innovative Gene Therapy SGT-212 Gains Buy Rating Amid Promising Preclinical Results and FDA Approval
Piper Sandler Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $20
Solid Biosciences (SLDB) Receives a Buy From Piper Sandler
Barclays Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $15
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Biomea Fusion (BMEA) and Solid Biosciences (SLDB)
William Blair Maintains Solid Biosciences(SLDB.US) With Buy Rating
Truist Financial Initiates Solid Biosciences(SLDB.US) With Buy Rating, Announces Target Price $16
Solid Biosciences Analyst Ratings
William Blair Maintains Solid Biosciences(SLDB.US) With Buy Rating
Solid Biosciences Receives Buy Rating Amid Promising Developments and Accelerated Approval Prospects for SGT-003
Wedbush Initiates Solid Biosciences(SLDB.US) With Buy Rating, Announces Target Price $16
H.C. Wainwright Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $16
HC Wainwright & Co. Reiterates Buy on Solid Biosciences, Maintains $16 Price Target
Solid Biosciences Initiated at Market Outperform by JMP Securities
Solid Biosciences Analyst Ratings